Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This clinical trial involves individuals who have been diagnosed with Acute Myeloid Leukemia
(AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), or
MDS/myeloproliferative neoplasm-unclassifiable (MDS/MPN-unclassifiable) and are planning to
have an allogeneic hematopoietic stem cell transplant ("bone marrow transplant"). The goal of
this research study is to (1) test the safety of adding the study drug, Venetoclax, to a
standard of care conditioning regimen for bone marrow transplantation as a possible means of
eliminating residual (left-over) disease prior to transplant and (2) to test the safety of
combination Venetoclax and azacitidine as "maintenance therapy" after transplant to possibly
prevent disease recurrence.
- The name of the study drug involved in this study is Venetoclax.
- It is expected that about 45 people will take part in this research study.